Olaparib is a PARP inhibitor used as a therapeutic treatment for breast cancer, particularly in patients with BRCA1 or BRCA2 mutations, as evidenced by its clinical expansion [1], [2] and its evaluation in phase 3 clinical trials [3], [4].